BioVector® WM88 人皮肤黑色素瘤细胞系 / BioVector® WM88 Human Skin Melanoma Cell Line

通用定义 / General Definition:BioVector® WM88 是一种源自人皮肤黑色素瘤 (Melanoma) 的原发性肿瘤细胞系。该细胞系处于黑色素瘤发展的垂直生长期 (Vertical Growth Phase, VGP)。在临床分期上，VGP 标志着肿瘤开始具备侵袭真皮层并获得转移潜能的关键阶段。WM88 携带黑色素瘤中最常见的 BRAF V600E 突变，使其成为研究 MAPK 信号通路传导、黑色素瘤侵袭机制以及评估 BRAF 抑制剂（如威罗菲尼）药效的重要实验模型。

BioVector® WM88 is a human skin Melanoma cell line derived from a primary tumor. It represents the Vertical Growth Phase (VGP) of melanoma development. Clinically, the VGP marks the critical transition where the tumor gains the ability to invade the dermis and acquires metastatic potential. WM88 carries the highly prevalent BRAF V600E mutation, making it an essential experimental model for studying MAPK signaling pathways, melanoma invasion mechanisms, and evaluating the efficacy of BRAF inhibitors (e.g., Vemurafenib).

BioVector® WM88 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® WM88 人皮肤黑色素瘤细胞

• 组织来源： 皮肤 (Skin)

• 疾病背景： 黑色素瘤 (原发灶，垂直生长期)

• 生长特性： 贴壁生长

• 细胞形态： 纺锤形或多角形，呈现黑色素瘤细胞典型的异质性。

2. 培养条件

• 基础培养基： BioVector® W489 培养基 或 MCDB153/L15 (4:1) 混合培养基（含 2mM L-谷氨酰胺）。

• 血清添加： 2% - 5% BioVector® 优质胎牛血清 (FBS)。

• 关键添加剂： 某些方案可能建议添加胰岛素。

• 培养环境： 37 摄氏度，5% CO2

• 传代比例： 1:2 至 1:4；建议在细胞汇合度达到 80%-90% 时进行传代。

3. 细胞应用

• 信号传导研究： 研究 BRAF V600E 突变驱动的下游 MAPK/ERK 通路活化。

• 侵袭与迁移： 评估黑色素瘤细胞从原发灶向深层组织浸润的动力学。

• 耐药性建模： 建立针对 BRAF/MEK 抑制剂的获得性耐药模型。

4. 注意事项

• 基因型验证： 鉴于黑色素瘤细胞的高度异质性，建议定期验证其 BRAF 突变状态。

• 生长速度： VGP 期的细胞通常比早期 RGP（径向生长期）细胞生长更快，需注意控制传代密度。

English Datasheet

1. General Product Information

• Product Name: BioVector® WM88 Human Skin Melanoma Cell Line

• Tissue Source: Skin

• Disease Context: Melanoma (Primary tumor, Vertical Growth Phase)

• Growth Properties: Adherent

• Morphology: Spindle-shaped or polygonal, showing characteristic melanoma cell heterogeneity.

2. Culture Conditions

• Basal Medium: BioVector® W489 Medium or a mixture of MCDB153 and L15 (4:1) supplemented with 2mM L-Glutamine.

• Serum Supplement: 2% - 5% BioVector® Fetal Bovine Serum (FBS).

• Supplements: Some protocols recommend the addition of insulin for optimal maintenance.

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:2 to 1:4 ratio; subculture when cells reach 80%-90% confluence.

3. Applications

• Signal Transduction: Investigating the activation of the MAPK/ERK pathway driven by the BRAF V600E mutation.

• Invasion and Migration: Assessing the kinetics of melanoma infiltration from the primary site into deeper dermal layers.

• Drug Resistance Modeling: Developing models for acquired resistance against BRAF or MEK inhibitors.

4. Key Usage Notes

• Genotype Authentication: Given the high heterogeneity of melanoma lines, periodic verification of the BRAF V600E mutation status is strongly recommended.

• Growth Management: VGP stage cells typically proliferate more rapidly than earlier RGP (Radial Growth Phase) cells; maintain a consistent subculturing schedule to prevent over-confluence.

注意 / Note: BioVector® WM88 应在生物安全二级 (BSL-2) 条件下操作。为保持其侵袭表型，建议使用较低百分比的血清和专门优化的黑色素瘤培养基。BioVector® WM88 should be handled under Biosafety Level 2 (BSL-2) conditions. To maintain its invasive phenotype, BioVector® recommends using low-serum concentrations and specialized, optimized melanoma media formulations.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net